Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia PharmaTSE:4579 60 Receivables Turnover is 0.51 as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 60/100 and a GF Value™ of 円310.86 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 840 Biotechnology companies, RaQualia Pharma ranks worse than 89.64% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. RaQualia Pharma's Revenue for the
three
months ended in Mar. 2026 was 円802 Mil. RaQualia Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was 円1,581 Mil.
Hence, RaQualia Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.51.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
RaQualia Pharma Receivables Turnover Related Terms
RaQualia Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, RaQualia Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Receivables Turnover of 0.51 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #753 out of 840 companies in the Biotechnology industry, placing it in the top 89.6%.
Is RaQualia Pharma's Receivables Turnover too high?
RaQualia Pharma's current Receivables Turnover is 0.51. The Biotechnology industry median Receivables Turnover is 5.28. RaQualia Pharma's value of 0.51 is 90.3% below this industry median. Based on the distribution chart, RaQualia Pharma ranks #753 out of 840 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RaQualia Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #753 out of 840 companies for Receivables Turnover. This places RaQualia Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.28. RaQualia Pharma's value of 0.51 is 90.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current Receivables Turnover of 0.51 is 90.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Receivables Turnover is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.86, compared to a current price of 円453.00 — trading 45.7% above its estimated fair value. The current Receivables Turnover is 0.51 and 90.3% below the Biotechnology industry median of 5.28. RaQualia Pharma's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Receivables Turnover is 0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued.
The current stock price of 円453.00 is trading 45.7% above its estimated GF Value™ of 円310.86.
GuruFocus considers RaQualia Pharma to be Significantly Overvalued.
Key valuation signals for TSE:4579:
Receivables Turnover: 0.51
GF Value™: 円310.86 vs. price of 円453.00 (45.7% above fair value)
Industry Position: 90.3% below the Biotechnology median (#753 of 840)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
60GF Score
Get the complete analysis for TSE:4579
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
